Related Experiment Video
Updated: Sep 17, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Afternoon discussion: Statistical issues in clinical trials conference on dose finding
Anna Heath1,2,3, Kelley M Kidwell4
1Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada.
None:
The adoption of innovative, model-based, and computationally intensive clinical trial designs is challenged by barriers including clinician engagement, regulatory acceptance, dissemination beyond major research institutions, and patient accrual. This session explored strategies to overcome these barriers. Key approaches discussed included the development of user-friendly software and interactive platforms to enhance transparency, open sharing of algorithms, and recognition of software contributions in academic publishing. Building collaborations with stakeholders predisposed to innovation, fostering interdisciplinary communication, and producing complementary methodological and clinical publications were emphasized as essential steps. Practical considerations for trials with small sample sizes included the use of adaptive designs, individualized trials, and alternative optimization strategies when traditional theoretical assumptions are infeasible. A major theme of the discussion was the importance of model assumptions in innovative designs. Questions were raised about the sensitivity of results to these assumptions and the robustness of methods, particularly under limited sample sizes. Addressing this requires extensive simulation studies across varied scenarios to assess operating characteristics. The focus should be on achieving clinically meaningful goals-such as identifying effective dose regions-rather than perfect model specification. Speakers emphasized the need to acknowledge and, when feasible, test assumptions post hoc, integrating such verification as secondary objectives in trial design. An iterative scientific process was encouraged, recognizing that trials not only serve immediate clinical goals but also advance broader scientific understanding. Assumptions provide a principled foundation for methodology, but thoughtful scrutiny of their realism was urged, given the risk of relying on overly strong or untestable premises. The potential of metaheuristic algorithms was highlighted for efficiently identifying optimal designs across different model assumptions, supporting robustness evaluations. Practical implementation should adapt optimal designs to stakeholder needs while preserving acceptable statistical efficiency. In sum, advancing the adoption of innovative designs requires improved communication, infrastructure, and methodological transparency, alongside careful evaluation of model assumptions and robustness.
More Related Videos
06:20Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
Published on: March 11, 2021
10:33Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation
Published on: September 4, 2017
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Clinical Trials: Overview
Dose-Response Relationship: Overview
Analysis of Population Pharmacokinetic Data
Dose-Response Relationship: Potency and Efficacy